is Larson, Officer. Chief Financial me everyone here to Thanks, Corey, our afternoon and joining Doug today us. good With
to commercial sequential going a hospital in pleased been continues PH LungFit call process we by team begin driven has the system seeing by quarterly to steady our as stating through the new their signings stream Let's start growth and significant using make This we our institutions. today's progress. are revenue onboarding with are how of
starts and the about since X team. contracts, and During Commercial years. new energy Air new Officer PH us, of one which X quarter, them our joined been only we their since LungFit upgraded months renew the hospitals shipping X began our X hospital to X Chief entire new has for brought months saw There's Beyond
We expect growth throughout and revenue sequential momentum this will continue this quarterly year. drive
respiratory PH for are possible staff nurses, key the stage tremendous our factor which of hospital a customers on ongoing each references great engagements. physicians, and A experience is our strengthening job for process team that of customer providing Beyond has of the potential best new course, success offering of device, to the administrators the ensure feedback we engagement positive Air LungFit existing therapists. to done are translates Most overwhelmingly importantly,
to the our we contracting TrillaMed on and team. engagement links, our several and pipeline, care Military and that supplementing GPOs robust advisory Building engage a to direct distribute sales now with veterans IDNs including us hospitals. health customer care have renowned with help place, and partnerships works Administration in and firm health
upgraded significantly, a efforts efforts. sales marketing which our our Additionally, provided been to boost have meaningful has
take are activities our postings. which media at conferences can and In social all a our much if see respiratory of improved, presence you addition, all you at look
FDA include for supplement PMA cardiac discussion the the to PH to the continues. LungFit with Turning interactive label surgery, expansion
updates information to quarter. the each will FDA provide investors provide request with that We and continue they to
the cardiac products United surgery As are currently States. in a no for reminder, approved nitric oxide
last the One market. about U.S. point
question November, strong FDA. shortly can we the Meeting, my feedback being, the version that expect quite to most system I AARC in Recall for submission next-generation PMA transport We this supplement in Annual system PH our common our for hospital. of get was capable demonstrated LungFit at and ready when LungFit PH to next-generation this with be the
earnings next We this on system call. on details will further provide quarter's
royalty us we the approval. recognize a payment Union with with other Outside treatment LungFit March conjunction Pacific distribution announced $X Getz allows Mark receive the than postoperative U.S., PH and Healthcare, Receiving Mark XX certification. from market will the this we under receive that with we in and in our of Along the Mark which with the as in to European indications December treatment of long-awaited as million infants the LungFit and on well adults PH based in covered peri weeks CE partner, countries approval children quarter. failure CE heart in certification milestone This pulmonary payments, are greater surgery. received hypertension that Asia gestation PH. The respiratory CE hypoxic triggered will LungFit
is South provide Europe, Getz Australia hospitals LungFit U.S. accelerate Asia to To Pacific East. ex schedule receiving PH to Asia of region in Middle authorization have market months throughout ahead than up America, teamed X and already business with the securing Mark. CE consultants less after the we sales,
We East. have new already high interest. contracts already X fact, And we in signed extremely seen progress in distributor have with the Middle
due unable [ the a PH supply with room or systems. oxide difficulties to not ] generates obtain air, cylinder-based reminder, use that nitric Cameron from areas logistical opportunity the associated where enormous opens LungFit to nitric world As hospitals do natural around in oxide up fact are oxide
Overall, since that XXXX expect inflection globally. the in point commercial few an impact and is in will U.S., which the the share make start PH, infrastructure. significant U.S. taking happening on new starting the fiscal to months, our market next in on to is LungFit our poised U.S. now the spring we The the market revenues back and half to of system XXXX believe updated in the of and Globally, thanks the we improved performance shipments see beyond. and
XXXX our fiscal be will will for in XXXX fiscal guidance June. call, revenue year-end which on We providing and held be conference
cancer. Beyond to Turning
patient of UNO, anti-PD-X therapy Ib approval Ib high regulatory cancer patients around ultra-high study be need. call X nitric The utilize late-stage will per XX%. therapy, than milliliters end UNO an because received unmet human a have who while they remains XXXX. now a XX,XXX which data XXX in anticipated gas, to Top begin our parts dose oxide of with original Ib low-volume for this low We of reported, reduction gas, line study from it Phase million. trial study the liter previously failed anti-PD-X area are combination calendar As utilized Phase will in over Phase or volume this of less concentration of
pleased for those therapy subsidiary with therapies you potentially encourage anti-PD-X transformational this I be for information the in Spectrum disorders Autism website is global visit market for the tumors. tens of advances all of focused Beyond from solid cancer more is to we the believe NeuroNOSour knows, that should of everyone on this am the billions as for groundbreaking therapy dollars. making. also As I year suffering
data in NeuroNOS leader few During the gene awarded understanding Board. to reality. what the we of and the Advisory December I begin later for the will in years, over more The Nobel a with his field in the therapy Prize in you website indicators path leading how made all get this across Chemistry the hope expect Dr. a next its idea meet human recently nitric first and to indications. for later is is of great future see calendar in bright studies, XXXX. to FDA of progress PH multiple the of paint and appointment revolutionary for groundbreaking these LungFit NeuroNOS Professor to which quarter, including as work eukaryotic a anticipated in NeuroNOS announced a in human an complete XXXX. year renowned Roger Kornberg XXXX to Kornberg,, Scientific come transcription oxide offers was molecular
team vision improving on need benefits of profitability to of Beyond the patients continue nitric will in the Air path of this lives the the and oxide.
Doug will turn I it Larson. CFO, over our to Now